Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | CXCR3 | P49682 | 11/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579481 | 0.87 | ALDH1A1 (0.59) | KCNH2HRH3CXCR3PDE10AALDH1A1 | |
| SCHEMBL1553514 | 0.83 | HRH3 (0.55) | KCNH2HRH3CXCR3PDE10AALDH1A1 | |
| SCHEMBL4582001 | 0.82 | SMN1; SMN2 (0.56) | KCNH2HRH3CXCR3PDE10AALDH1A1 | |
| SCHEMBL1553792 | 0.82 | POLB (0.50) | KCNH2HRH3CXCR3ALDH1A1NPC1 | |
| SCHEMBL1553167 | 0.82 | CXCR3 (0.53) | CXCR3PDE10AALDH1A1 | |
| SCHEMBL1553360 | 0.81 | MAPK1 (0.46) | KCNH2HRH3CXCR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL1553708 | 0.81 | MEN1 (0.50) | KCNH2HRH3CXCR3 | |
| SCHEMBL1553134 | 0.79 | SMN1; SMN2 (0.63) | ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1554042 | 0.78 | HSD17B10 (0.45) | CXCR3PDE10AALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL12659722 | 0.77 | MAPT (0.61) | KCNH2HRH3CXCR3ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748440-B2 | Quinazolinone modulators of nuclear receptors | EXELIXIS, INC. (US) | 2014-06-10 | — | — | US | claimed |
| EP-1521746-B1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-04-27 | — | — | EP | claimed |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | claimed |
| US-8748440-B2 | Quinazolinone modulators of nuclear receptors | EXELIXIS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| EP-1521746-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-Ceptor Therapeutics, Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| WO-2003076418-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | KCNH2 4581/4885HRH3 886/4885CXCR3 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.